Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management
Top Cited Papers
Open Access
- 22 June 2011
- journal article
- practice guideline
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 27 (7), 639-653
- https://doi.org/10.1002/dmrr.1239
Abstract
The Cardiovascular Autonomic Neuropathy (CAN) Subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy worked to update CAN guidelines, with regard to epidemiology, clinical impact, diagnosis, usefulness of CAN testing, and management. CAN is the impairment of cardiovascular autonomic control in the setting of diabetes after exclusion of other causes. The prevalence of confirmed CAN is around 20%, and increases up to 65% with age and diabetes duration. Established risk factors for CAN are glycaemic control in type 1 and a combination of hypertension, dyslipidaemia, obesity, and glycaemic control in type 2 diabetes. CAN is a risk marker of mortality and cardiovascular morbidity, and possibly a progression promoter of diabetic nephropathy. Criteria for CAN diagnosis and staging are: (1) one abnormal cardiovagal test result identifies possible or early CAN; (2) at least two abnormal cardiovagal test results are required for definite or confirmed CAN; and (3) the presence of orthostatic hypotension in addition to abnormal heart rate test results identifies severe or advanced CAN. Progressive stages of CAN are associated with increasingly worse prognosis. CAN assessment is relevant in clinical practice for (1) diagnosis of CAN clinical forms, (2) detection and tailored treatment of CAN clinical correlates (e.g. tachycardia, orthostatic hypotension, non‐dipping, QT interval prolongation), (3) risk stratification for diabetic complications and cardiovascular morbidity and mortality, and (4) modulation of targets of diabetes therapy. Evidence on the cost‐effectiveness of CAN testing is lacking. Apart from the preventive role of intensive glycaemic control in type 1 diabetes, recommendations cannot be made for most therapeutic approaches to CAN. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 57 references indexed in Scilit:
- Heart Rate Variability Predicts ESRD and CKD-Related HospitalizationJournal of the American Society of Nephrology, 2010
- Type 2 diabetes mellitus and the risk of sudden cardiac arrest in the communityReviews in Endocrine and Metabolic Disorders, 2010
- Effects of Prior Intensive Insulin Therapy on Cardiac Autonomic Nervous System Function in Type 1 Diabetes MellitusCirculation, 2009
- The consensus statement on the definition of orthostatic hypotension: a revisit after 13 yearsJournal of Hypertension, 2009
- Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 DiabetesJama-Journal Of The American Medical Association, 2009
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesThe New England Journal of Medicine, 2009
- Relationship Between Risk Factors and Mortality in Type 1 Diabetic Patients in EuropeDiabetes Care, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- 2007 ESH‐ESC Guidelines for the management of arterial hypertensionBlood Pressure, 2007